drugset / Trial / NCT05089643
Anrotinib in Combination With Capecitabine in Advanced Triple Negative Breast Cancer
NaSingle-groupOpen-labelTreatment
Summary
The hypothesis of this study is to discover if the capecitabine plus Anlotinib can shrink or slow the growth of pretreated advanced TNBC. It is a single-arm phase II clinical study of capecitabine combined with antinib in the treatment of recurrent or metastatic triple-negative breast cancer
Timeline
- Start
- 2019-04-11
- Primary completion
- 2019-04-15
- Completion
- 2022-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capecitabine | Small molecule | 1000 mg/m2 | Oral |
| Subject | Catequentinib | Small molecule | 10 mg | Oral |